ArticleMycoses2025
Utility of MALDI-ToF MS for Recognition and Antifungal Susceptibility of Nannizzia, an Underestimated Group of Dermatophytes.
Article in Mycoses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance.Journal of fungi (Basel, Switzerland) · 2026Review
- Pathogen Identification and Treatment ofInsects · 2025Article
- Utility of MALDI-ToF MS for Recognition and Antifungal Susceptibility of Nannizzia, an Underestimated Group of Dermatophytes.Mycoses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundGeophilic Nannizzia dermatophytes are increasingly implicated in stubborn skin, hair, and nail infections, yet MALDI-TOF MS evaluations and antifungal-susceptibility data have focused almost exclusively on N. gypsea. Biochemical profiles and MICs cut-offs are limited.
objectivesTo benchmark two commercial MALDI-TOF MS libraries and to determine in vitro activity of eight antifungals against a genus-wide panel of Nannizzia species.
methodsOne-hundred-and-three ITS-confirmed isolates representing 12 species were grown on potato-dextrose agar (PDA) for 7-14 days. Spectra were acquired with (i) the MSI-2 Dermatophyte Library after 4-14 days' PDA incubation (100 cultures) and (ii) the Bruker MALDI Biotyper Filamentous-Fungi Library 6.0/2023 after ≤ 3 days' growth in Sabouraud-dextrose broth (SDB) (73 cultures). BCCM/IHEM strains could not be evaluated on the Biotyper because of licence restrictions, leaving 73 non-duplicate isolates for direct MSI-2 vs MBT comparison. EUCAST E.Def 11.0 micro-broth dilution determined MICs for eight agents.
resultsMSI-2 achieved its highest accuracy with PDA day-7 cultures (45/73, 62%), whereas the liquid Biotyper protocol yielded 49/73 correct identifications (67%) within four days. Accepting low-confidence scores (≥ 1.7) from either library increased overall accuracy to 73%. MSI-2 remained superior for N. gypsea (73%) and uniquely detected N. nana (50%), which is absent from the current Biotyper release. Conversely, the Biotyper outperformed MSI-2 for N. incurvata, N. fulva, and N. praecox. Six very rare species (N. lorica, N. aenigmatica, N. corniculata, N. duboisii, N. perplicata, N. polymorpha) were not recognised by either database. Terbinafine displayed the lowest geometric mean MIC (0.009 mg/L); fluconazole and griseofulvin showed the highest values, and one US N. fulva isolate exhibited elevated itraconazole/voriconazole MICs (1 mg/L).
conclusionsDiagnostic coverage of Nannizzia remains incomplete. Expanding commercial MALDI-ToF MS libraries with spectra from rare species and performing routine susceptibility testing are essential to optimise patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.